Loading clinical trials...
Loading clinical trials...
A Multi-Center, Randomized, Open-Label Study Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women
Conditions
Interventions
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Locations
5
United States
Anaheim, California, United States
DeLand, Florida, United States
Miami, Florida, United States
Orlando, Florida, United States
San Antonio, Texas, United States
Start Date
September 1, 2016
Primary Completion Date
December 1, 2016
Completion Date
March 1, 2017
Last Updated
April 28, 2022
Lead Sponsor
AMAG Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions